Weight Loss Drug Biosimilar Market Global Report 2026

The weight loss drug biosimilar market size has grown exponentially in recent years. It will grow from $1.21 billion in 2025 to $1.53 billion in 2026 at a compound annual growth rate (CAGR) of 26.6%. The growth in the historic period can be attributed to dominance of branded glp-1 therapies, rising global obesity prevalence, limited biosimilar regulatory frameworks, high biologics production costs, strong physician preference for originator drugs.

The weight loss drug biosimilar market size is expected to see exponential growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to expiry of key biologic patents, expansion of biosimilar development pipelines, increasing healthcare cost containment policies, rising adoption in emerging markets, growth of long-term metabolic disease management programs. Major trends in the forecast period include GLP-1 biosimilar patent expiration driven market entry acceleration, intensifying price competition and biosimilar tendering in obesity therapeutics, expanding regulatory harmonization for biosimilar interchangeability approvals, growth of cold chain dependent biologics distribution networks for metabolic injectables, increasing payer and formulary driven access restrictions for branded weight loss biologics.

The increasing prevalence of obesity is anticipated to drive the growth of the weight loss drug biosimilar market in the coming years. Obesity is a medical condition marked by excessive accumulation of body fat, which elevates the risk of health complications such as diabetes, cardiovascular diseases, and hypertension. The growing number of obese and overweight individuals is mainly attributed to higher consumption of calorie-dense processed foods along with declining levels of physical activity. Weight loss drug biosimilars are used in obesity management by replicating approved anti-obesity biologic therapies that help regulate appetite, enhance satiety, and support metabolic regulation to promote weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government department, approximately 64.5% of adults in England were overweight or living with obesity in 2023-2024, increasing from 64.0% in 2022-2023, indicating a continued upward trend. Therefore, the increasing prevalence of obesity is contributing to the growth of the weight loss drug biosimilar market.

Major companies operating in the weight loss drug biosimilar market are focusing on improving access to affordable GLP-1-based therapies, expanding drug development collaborations, enhancing dosage and formulation options, and addressing the rising prevalence of obesity and lifestyle-related metabolic disorders through scalable and cost-efficient treatment solutions across emerging and developed markets. Affordable GLP-1-based therapies are treatments that use glucagon-like peptide-1 receptor agonists to manage conditions such as type 2 diabetes and obesity while ensuring greater financial accessibility for a wider patient population. For instance, in December 2024, Emcure Pharmaceuticals Limited, an India-based pharmaceutical company, launched Poviztra in India, representing its entry into the rapidly growing obesity and weight-management treatment segment. The injectable therapy, a once-weekly GLP-1 medication, was developed in partnership with Novo Nordisk, a Denmark-based healthcare company, and is positioned as a more affordable option compared with existing branded weight-loss medications. It is offered in multiple dosage strengths and is designed to support long-term weight management in combination with diet and lifestyle modifications. The launch enhances Emcure’s footprint in cardiometabolic care and improves access to advanced obesity treatments in India, where demand for medical weight-management solutions is increasing rapidly due to growing lifestyle-related health challenges.

In April 2024, Biocon Biologics, an India-based biosimilars company, entered into a partnership with Biomm SA to commercialize semaglutide for the treatment of type 2 diabetes in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply of the drug, while Biomm will manage regulatory filings and oversee the product’s launch and commercialization activities in Brazil. Biomm SA is a Brazil-based biotechnology and biopharmaceutical company.

Major companies operating in the weight loss drug biosimilar market report are Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Alvotech, Amgen Inc., Biocon Limited, Celltrion Inc., Cipla Limited, Dr. Reddy’s Laboratories Limited, Emcure Pharmaceuticals Limited, Eris Lifesciences Limited, Glenmark Pharmaceuticals Limited, Hetero Labs Limited, Huadong Medicine, Jiuyuan Genetic Biopharmaceutical, Lupin Limited, Mankind Pharma, Oncosimis Biotech, Samsung Bioepis, Sandoz Group AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, Viatris Inc., Wockhardt, Zydus Lifesciences Limited.

North America was the dominating region in the weight loss drug biosimilar market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the weight loss drug biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the weight loss drug biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.